Business Context and Reporting Period
This Form 8-K is a current report filed by Conduit Pharmaceuticals Inc. (trading symbol: CDT) on June 3, 2025. The filing addresses Item 5.08 regarding shareholder director nominations and the scheduling of the 2025 Annual Meeting of Stockholders.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is strictly procedural and contains no financial performance data.
Material Changes
The primary material change disclosed is the rescheduling of the 2025 Annual Meeting of Stockholders. The Board of Directors has set the meeting date for August 5, 2025, which is more than 30 days prior to the anniversary of the 2024 Annual Meeting. Consequently, the record date for the meeting is established as July 3, 2025.
Guidance, Outlook, and Management Commentary
There is no financial guidance, outlook, or management commentary regarding business operations in this filing. The document focuses on corporate governance deadlines:
- Proposal Deadline: Stockholders wishing to submit proposals for inclusion in proxy materials under Rule 14a-8 or to nominate directors under the Company's bylaws must submit written notice by the close of business on June 17, 2025.
- Submission Address: Notices must be sent to the Company Secretary at the principal executive offices in Naples, FL.
Key Facts for Investor Verification
- Meeting Date: August 5, 2025.
- Record Date: July 3, 2025.
- Submission Deadline: June 17, 2025, for shareholder proposals and director nominations.
- Securities Listed: Common Stock (CDT) and Redeemable Warrants (CDTTW) on The Nasdaq Stock Market LLC.
- Company Status: Identified as an emerging growth company.